Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Kohne, Claus-Henning
Hofheinz, Ralf
Mineur, Laurent
Letocha, Henry
Greil, Richard
Thaler, Josef
Twomey, Brian
Oliner, Kelly Smith
Boedigheimer, Michael
Terwey, Jan-Henrik
Karthaus, Meinolf
机构：
[1] Onkol Klinikum Oldenburg, Oldenburg, Germany
[2] Univ Hosp Mannheim, Mannheim, Germany
[3] Inst St Catherine, Dept Radiotherapy & Oncol, Avignon, France
[4] Vasteras Hosp, Oncol Clin, Vasteras, Sweden
[5] Univ Klinikum PMU, Salzburg, Austria
[6] Klinikum Wels Grieskirchen, Dept Hematol & Med Oncol, Wels, Austria
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Amgen Inc, Med Sci, Thousand Oaks, CA 91320 USA
[9] Amgen Europe GmbH, Zug, Switzerland
[10] Klinikum Harlaching, Klinikum Neuperlach, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.731
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
731
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf D.
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
    Tebbutt, N. C.
    Kotasek, D.
    Burris, H. A., III
    Schwartzberg, L. S.
    Hurwitz, H.
    Stephenson, J.
    Adewoye, H.
    Sun, Y.
    Ye, Y.
    Goldstein, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Oliner, K. S.
    Demonty, G.
    Koehne, C. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S375 - S376
  • [4] Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    Malapelle, Umberto
    Rosati, Gerardo
    Lotesoriere, Claudio
    Tamburini, Emiliano
    Colombo, Alfredo
    Pepe, Francesco
    Cardone, Claudia
    Leone, Alessandra
    Vitagliano, Carlo
    Russo, Gianluca
    Troncone, Giancarlo
    Giannarelli, Diana
    De Stefano, Alfonso
    Budillon, Alfredo
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [5] Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) plus FOLFIRI treatment
    Karthaus, Meinolf
    Van Den Eynde, Marc
    Mineur, Laurent
    Thaler, Josef
    Koukakis, Reija
    Berkhout, Marloes
    Gallego, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Tumor response as important parameter during first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Demonty, G.
    Koehne, C. -H
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 73 - 73
  • [7] Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Greil, R.
    Letocha, H.
    Gamelin, E.
    Thaler, J.
    Hofheinz, R.
    Mineur, L.
    Fernebro, E.
    Karthaus, M.
    Wright, L.
    Koehne, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab (Pmab) for metastatic colorectal cancer (mCRC)
    Koehne, C. -H.
    Peeters, M.
    Carrato, A.
    Coriat, R.
    Rivera, F.
    Koukakis, R.
    Demonty, G.
    Geissler, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 124 - +
  • [9] PATIENT-REPORTED OUTCOMES (PRO) IN A FIRST-LINE STUDY (20060314) OF PANITUMUMAB plus FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Karthaus, M.
    Resch, G.
    Mineur, L.
    Hofheinz, R.
    Greil, R.
    Letocha, H.
    Fernebro, E.
    Gamelin, E.
    DeCosta, L.
    Koehne, C.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 75 - 75
  • [10] Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC)
    Rivera Herrero, F.
    Bachet, J-B.
    Modest, D. P.
    de Braud, F.
    Pietrantonio, F.
    Koukakis, R.
    Demonty, G.
    Douillard, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345